Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16(INK4a) and p19(ARF), is a candidate for the plasmacytoma susceptibility locus, Pctr1

Por Zhang, Shuling, Ramsay, Edward S., Mock, Beverly A.
Publicado em 1998

A Mouse Homeo Box Gene, Hox-1.5, and the Morphological Locus, Hd, Map to within 1 Cm on Chromosome 6

Por Mock, Beverly A., D'Hoostelaere, Lawrence A., Matthai, Roberta, Huppi, Konrad
Publicado em 1987

Molecular Pathways: Increased Susceptibility to Infection Is a Complication of mTOR Inhibitor Use in Cancer Therapy

Por Eiden, Adrian M., Zhang, Shuling, Gary, Joy M., Simmons, John K., Mock, Beverly A.
Publicado no Clin Cancer Res (2015)

A novel KIT-deficient mouse mast cell model for the examination of human KIT-mediated activation responses

Por Smrž, Daniel, Bandara, Geethani, Zhang, Shuling, Mock, Beverly A., Beaven, Michael A., Metcalfe, Dean D., Gilfillan, Alasdair M.
Publicado em 2013

Mndal, a new interferon-inducible family member, is highly polymorphic, suppresses cell growth, and may modify plasmacytoma susceptibility

Por Zhang, Ke, Kagan, Daniel, DuBois, Wendy, Robinson, Richard, Bliskovsky, Valery, Vass, William C., Zhang, Shuling, Mock, Beverly A.
Publicado em 2009

Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene

Por Bliskovsky, Valery, Ramsay, Edward S., Scott, John, DuBois, Wendy, Shi, Wei, Zhang, Shuling, Qian, Xiaolan, Lowy, Douglas R., Mock, Beverly A.
Publicado em 2003

Small Molecule Microarrays Enable the Identification of a Selective, Quadruplex-Binding Inhibitor of MYC Expression

Por Felsenstein, Kenneth M., Saunders, Lindsey B., Simmons, John K., Leon, Elena, Calabrese, David R., Zhang, Shuling, Michalowski, Aleksandra, Gareiss, Peter, Mock, Beverly A., Schneekloth, John S.
Publicado no ACS Chem Biol (2015)

Efficiency Alleles of the Pctr1 Modifier Locus for Plasmacytoma Susceptibility

Por Zhang, Shuling-L., DuBois, Wendy, Ramsay, Edward S., Bliskovski, Valeri, Morse, Herbert C., Taddesse-Heath, Leki, Vass, William C., DePinho, Ronald A., Mock, Beverly A.
Publicado em 2001

cFOS-SOX9 Axis Reprograms Bone Marrow-Derived Mesenchymal Stem Cells into Chondroblastic Osteosarcoma

Por He, Yunlong, Zhu, Wentao, Shin, Min Hwa, Gary, Joy, Liu, Chengyu, Dubois, Wendy, Hoover, Shelley B., Jiang, Shunlin, Marrogi, Eryney, Mock, Beverly, Simpson, R. Mark, Huang, Jing
Publicado no Stem Cell Reports (2017)

mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells

Por Smrž, Daniel, Kim, Mi-Sun, Zhang, Shuling, Mock, Beverly A., Smržová, Šárka, DuBois, Wendy, Simakova, Olga, Maric, Irina, Wilson, Todd M., Metcalfe, Dean D., Gilfillan, Alasdair M.
Publicado em 2011

B Cell-specific Deficiencies in mTOR Limit Humoral Immune Responses()

Por Zhang, Shuling, Pruitt, Margaret, Tran, Dena, Bois, Wendy Du, Zhang, Ke, Patel, Rushi, Hoover, Shelley, Simpson, R. Mark, Simmons, John, Gary, Joy, Snapper, Clifford M., Casellas, Rafael, Mock, Beverly A.
Publicado em 2013

TORC1 and class I HDAC inhibitors synergize to suppress mature B cell neoplasms

Por Simmons, John K., Patel, Jyoti, Michalowski, Aleksandra, Zhang, Shuling, Wei, Bih-Rong, Sullivan, Patrick, Gamache, Ben, Felsenstein, Kenneth, Kuehl, W. Michael, Simpson, R. Mark, Zingone, Adriana, Landgren, Ola, Mock, Beverly A.
Publicado em 2013

Constitutive reductions in mTOR alter cell size, immune cell development, and antibody production

Por Zhang, Shuling, Readinger, Julie A., DuBois, Wendy, Janka-Junttila, Mirkka, Robinson, Richard, Pruitt, Margaret, Bliskovsky, Val, Wu, Julie Z., Sakakibara, Kaori, Patel, Jyoti, Parent, Carole A., Tessarollo, Lino, Schwartzberg, Pamela L., Mock, Beverly A.
Publicado em 2011

Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity

Por Ou, Oliver, Huppi, Konrad, Chakka, Sirisha, Gehlhaus, Kristen, Dubois, Wendy, Patel, Jyoti, Chen, Jinqiu, Mackiewicz, Mark, Jones, Tamara L, Pitt, Jason J., Martin, Scott E., Goldsmith, Paul, Simmons, John K., Mock, Beverly A., Caplen, Natasha J.
Publicado no Cancer Lett (2014)

Increased mammalian lifespan and a segmental and tissue-specific slowing of aging following genetic reduction of mTOR expression

Por Wu, J. Julie, Liu, Jie, Chen, Edmund B., Wang, Jennifer J., Cao, Liu, Narayan, Nisha, Fergusson, Marie M., Rovira, Ilsa I., Allen, Michele, Springer, Danielle A., Lago, Cory U., Zhang, Shuling, DuBois, Wendy, Ward, Theresa, deCabo, Rafael, Gavrilova, Oksana, Mock, Beverly, Finkel, Toren
Publicado em 2013

Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation

Por Simmons, John K., Michalowski, Aleksandra M., Gamache, Benjamin J., DuBois, Wendy, Patel, Jyoti, Zhang, Ke, Gary, Joy, Zhang, Shuling, Gaikwad, Snehal, Connors, Daniel, Watson, Nicholas, Leon, Elena, Chen, Jin-Qiu, Kuehl, W. Michael, Lee, Maxwell P., Zingone, Adriana, Landgren, Ola, Ordentlich, Peter, Huang, Jing, Mock, Beverly A.
Publicado no Mol Cancer Ther (2017)

mTOR intersects antibody-inducing signals from TACI in marginal zone B cells

Por Sintes, Jordi, Gentile, Maurizio, Zhang, Shuling, Garcia-Carmona, Yolanda, Magri, Giuliana, Cassis, Linda, Segura-Garzón, Daniel, Ciociola, Alessandra, Grasset, Emilie K., Bascones, Sabrina, Comerma, Laura, Pybus, Marc, Lligé, David, Puga, Irene, Gutzeit, Cindy, He, Bing, DuBois, Wendy, Crespo, Marta, Pascual, Julio, Mensa, Anna, Aróstegui, Juan Ignacio, Juan, Manel, Yagüe, Jordi, Serrano, Sergi, Lloreta, Josep, Meffre, Eric, Hahne, Michael, Cunningham-Rundles, Charlotte, Mock, Beverly A., Cerutti, Andrea
Publicado no Nat Commun (2017)